Product Description
It is hypothesized that steady-state levels of KB001-A in CF subjects with airway Pa infection will be safe and well-tolerated, and will increase the time-to-need for antibiotic treatment (IV, inhaled, or oral) for worsening of respiratory tract signs and symptoms compared with placebo.
Mechanisms of Action: PcrV Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Humanigen
Company Location: BURLINGAME CA 94010
Company CEO: Cameron Durrant
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cystic Fibrosis|Pseudomonas Infections|Pneumonia, Ventilator-Associated
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| KB001-A | P2 |
Completed |
Cystic Fibrosis |
2014-11-01 |
2019-03-19 |
Treatments |
|
| KB001-04 | P2 |
Completed |
Pseudomonas Infections|Pneumonia, Ventilator-Associated |
2009-03-01 |
2019-03-22 |
Treatments |
|
| KB001-03 | P2 |
Completed |
Pseudomonas Infections|Cystic Fibrosis |
2009-03-01 |
2019-03-18 |
Treatments |
|
| 2007-006764-29 | P2 |
Active, not recruiting |
Unknown |
2009-02-25 |
2022-03-12 |
Treatments |